E7389 28 Day Cycle + E7389 21 Day Cycle
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small-Cell Lung Carcinoma
Conditions
Non-Small-Cell Lung Carcinoma
Trial Timeline
Dec 1, 2004 → —
NCT ID
NCT00100932About E7389 28 Day Cycle + E7389 21 Day Cycle
E7389 28 Day Cycle + E7389 21 Day Cycle is a phase 2 stage product being developed by Eisai for Non-Small-Cell Lung Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00100932. Target conditions include Non-Small-Cell Lung Carcinoma.
What happened to similar drugs?
7 of 20 similar drugs in Non-Small-Cell Lung Carcinoma were approved
Approved (7) Terminated (6) Active (9)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00100932 | Phase 2 | Completed |
Competing Products
20 competing products in Non-Small-Cell Lung Carcinoma